<h4>Background</h4>Abemaciclib plus fulvestrant was approved in Europe following publication of the MONARCH-2 trial and recommended to enter the NICE Cancer Drugs Fund for HR+/HER2- advanced breast cancer. This evidence concerns the gene HR and breast cancer.